
Opinion|Videos|December 4, 2024
Case 1: Metastatic Castration- Sensitive Prostate Cancer (mCSPC)
Key Takeaways
Panelists discuss how the management of metastatic castration-sensitive prostate cancer involves a multidisciplinary approach, utilizing androgen deprivation therapy, chemotherapy, and novel agents to control disease progression and improve patient survival.
Advertisement
Episodes in this series
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Annual ACS NCDB report details national trends in prostate cancer care
2
Treatment Selection in Advanced Prostate Cancer
3
FDA provides guidance on development pathway for testosterone therapy for women
4
Docetaxel plus tumor-targeting IL-12 yields promising activity in mCRPC
5


